RVX-208 is the only Apo-Al/HDL drug to be highlighted
TSX Exchange Symbol: RVX
CALGARY, July 18 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce that Resverlogix's lead drug is
featured prominently in an article titled "Emerging Antidyslipidemic Drugs",
which appears in the current edition of Expert Opinion of Emerging Drugs, a
well respected scientific journal for the pharmaceutical industry. The article
written by Drs.' Pollex, Joy and Hegele provides an overview of current and
upcoming dyslipidemic drugs.
"To be the only ApoA-l/HDL drug highlighted in an esteemed journal such
as Expert Opinion of Emerging Drugs speaks volumes as to the excitement felt
in the scientific community for our lead drug RVX-208," stated
Donald McCaffrey, President and CEO of Resverlogix. "The data provided to the
authors was our preclinical data. The Phase 1a data which we recently
announced illustrated very similar trending as the African Green Monkey data
of increased ApoA-I production and HDL functionality, thus our enthusiasm
continues to build as we head into our Phase 1b/2a trial later this year."
RVX-208 is a first-in-class small molecule that facilitates endogenous
ApoA-I production. It is positioned as one of the most promising emerging
drugs in the treatment of atherosclerosis, the largest medical market in the
world with a critical unmet need. To the Company's knowledge RVX-208 is the
only novel small molecule that is specifically designed to increase ApoA-I
production. Consequently this raises functional HDL levels which in turn
enhance reverse cholesterol transport, atherosclerosis regression and
ultimately reduction of major adverse cardiovascular events (MACE).
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com; Ken
Lebioda, SVP Business & Corporate Dev't, Resverlogix Corp., Phone: (403)
254-9252, Email: Ken@resverlogix.com; Website: www.resverlogix.com